UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2015
Commission File Number 000-50112
RepliCel Life Sciences Inc.
(Translation of registrant’s name into English)
Suite 2020 – 401 West Georgia Street, Vancouver, British Columbia V6B 5A1
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
SUBMITTED HEREWITH
| 99.1 | Press Release dated August 3, 2015 - RepliCel Presenting at InvestMNT Investor Conference in Minneapolis |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RepliCel Life Sciences Inc.
/s/ Brooke Hurford
Brooke Hurford, Secretary
Date: August 3, 2015
Exhibit 99.1
RepliCel Presenting at InvestMNT Investor Conference in Minneapolis
Conference attracts investment professionals in the Twin Cities area
VANCOUVER, BC, Aug. 3, 2015 /CNW/ - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that RepliCel's CEO, David Hall, will be presenting at the InvestMNT conference held in Minneapolis, Minnesota on August 5th at 8:15 AM local time. Hall's presentation will highlight RepliCel's 18-month milestones including CE Mark for its RCI-02 dermal injector for sale in Europe, clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical trials in Canada and Germany, as well as Shiseido's proposed pattern baldness clinical trial in Japan using RepliCel's RCH-01 (hair) product. The conference is hosted by the CFA Society of Minnesota and will take place at the Schulze School of Entrepreneurship, University of St. Thomas, Minneapolis Campus, 1000 LaSalle Avenue, Minneapolis. To learn more about the conference or if you're interested in attending, click here.
About InvestMNT
This year's InvestMNT conference will feature approximately 60 companies hosted by the CFA Society Minnesota, a professional organization
for investment professionals located in the Twin Cities and throughout the Upper Midwest region consisting of approximately 1,300
members in five states, across a broad scope of firms.
About RepliCel
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit
of healthy cells required for normal healing and function. The company's RCT-01, RCS-01, and RCH-01 cell therapies are designed
to treat chronic tendinosis, damaged or aging skin, and pattern baldness. All product candidates are based on RepliCel's innovative
technology utilizing cell populations isolated from a patient's own healthy hair follicles. The company has also developed a propriety
injection device optimized for the administration of its products and licensable for use with other dermatology applications.
Visit www.replicel.com for additional information.
For more information please contact:
MEDIA:
Tammey George, Director of Communications
Telephone: 604-248-8696 / tg@replicel.com
INVESTOR RELATIONS:
Lee Buckler, VP Business & Corporate Development
Telephone: 604-248-8693 / lee@replicel.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE RepliCel Life Sciences Inc.
%CIK: 0001205059
CO: RepliCel Life Sciences Inc.
CNW 07:00e 03-AUG-15